Periodic/Sector reports
Healthcare: Acuity Cushions Soft Volumes; Valuations Offer Opportunity
OVERWEIGHT (Maintained)
Analyst
Highlights
- Revenue intensity cushions softer volumes. MIKA’s high-complexity revenue grew 25.2% yoy, while SILO’s revenue per inpatient day rose 10.2%, supporting net profit growths of 6.7% and 22.1%, respectively. HEAL lagged, with revenue per inpatient day declining 1% and its out-of-pocket segment contracting 18.8%.
- Asset productivity and capital efficiency become increasingly important. HEAL’s bed capacity expanded 8.2% against a 3.2% growth in inpatient days, while MIKA’s ROIC excluding landbank declined to 37.9% from 42.4%. SILO’s net gearing rose to 55.2% from 4.8% following its hospital property acquisitions.
- Maintain OVERWEIGHT; prefer MIKA and KLBF. Depressed valuations offer attractive opportunities despite earnings uncertainty. MIKA offers established specialty-care capabilities, strong profitability and Rp2.7t in net cash, while KLBF provides exposure to volume-led growth, market-share gains and a Rp5.3t net cash position.
Analysis
- Demand is turning selective: volume is soft, acuity is holding. In 9M26, inpatient admissions fell 3.6% yoy at Mitra Keluarga Karyasehat (MIKA), driven by softer National Health Insurance (BPJS) patient volume, while Medikaloka Hermina (HEAL) and Siloam International Hospitals (SILO) recorded modest inpatient admission growth of 3.2% and 2.0%. Beyond tighter BPJS referral controls, softer household spending appears to be contraining self-funded healthcare spending with HEAL’s out-of-pocket segment contracting 18.8% yoy (vs +22.4% growth in its insurance and corporate segment). While patients may increasingly defer less urgent treatments, demand for higher-complexity care appers relatively resilient. This is reflected in MIKA’s 25.2% growth in high-complexity revenue. We see an increasing shift from volume-driven towards acuity and case mix-led growth, favouring operators with established speciality-care capabilities.
- Revenue intensity carrying earnings, but conversion varies across operators. In 9M26, the strong growth from high-complexity revenue lfited the segment contritbution to revenue to 28% (vs 9M24: 24%), while SILO’s revenue per patient day rose 10.2%. The stronger revenue intensity supported 8.2% MIKA’s EBITDA growth of 8.2% and SILO’s 17.8%, translating into net profit growths of 6.7% and 22.1% respectively. In contrast, HEAL’s revenue per inpatient day declined 1%, despite rising revenue contribution from non-BPJS patients. While stronger revenue intensity cannot indefinitely compensate for weak utilisation, the earnings resilience at MIKA and SILO challenges the narrative of a sector in structural earnings decline.
- Slower demand growth puts greater emphasis on asset productivity. In 9M26, HEAL expanded its bed capacity by 8.2% against just a 3.2% growth in inpatient days, while MIKA’s inpatient days fell 6% despite a 1.6% capacity increase. Consequently, HEAL’s bed occupancy rates (BOR) fell by 3.7ppt to 67.9% and MIKA’s BOR dropped 4.2ppt to 52.6%, while SILO’s remained broadly stable at 62.5%. The trade-off between expansion and shareholder returns is becoming increasingly evident - MIKA’s ROIC (excluding landbank) fell to 37.9% from 42.4%, higher depreciation drove HEAL’s 14.8% yoy net profit decline in 9M26, and SILO’s hospital property acquisitions materially increased its financial leverage, with net gearing ratio rising to 55.2% at end-Sep 26 from 4.8% at end-25.
Highlights
- Revenue intensity cushions softer volumes. MIKA’s high-complexity revenue grew 25.2% yoy, while SILO’s revenue per inpatient day rose 10.2%, supporting net profit growths of 6.7% and 22.1%, respectively. HEAL lagged, with revenue per inpatient day declining 1% and its out-of-pocket segment contracting 18.8%.
- Asset productivity and capital efficiency become increasingly important. HEAL’s bed capacity expanded 8.2% against a 3.2% growth in inpatient days, while MIKA’s ROIC excluding landbank declined to 37.9% from 42.4%. SILO’s net gearing rose to 55.2% from 4.8% following its hospital property acquisitions.
- Maintain OVERWEIGHT; prefer MIKA and KLBF. Depressed valuations offer attractive opportunities despite earnings uncertainty. MIKA offers established specialty-care capabilities, strong profitability and Rp2.7t in net cash, while KLBF provides exposure to volume-led growth, market-share gains and a Rp5.3t net cash position.
Analysis
- Demand is turning selective: volume is soft, acuity is holding. In 9M26, inpatient admissions fell 3.6% yoy at Mitra Keluarga Karyasehat (MIKA), driven by softer National Health Insurance (BPJS) patient volume, while Medikaloka Hermina (HEAL) and Siloam International Hospitals (SILO) recorded modest inpatient admission growth of 3.2% and 2.0%. Beyond tighter BPJS referral controls, softer household spending appears to be contraining self-funded healthcare spending with HEAL’s out-of-pocket segment contracting 18.8% yoy (vs +22.4% growth in its insurance and corporate segment). While patients may increasingly defer less urgent treatments, demand for higher-complexity care appers relatively resilient. This is reflected in MIKA’s 25.2% growth in high-complexity revenue. We see an increasing shift from volume-driven towards acuity and case mix-led growth, favouring operators with established speciality-care capabilities.
- Revenue intensity carrying earnings, but conversion varies across operators. In 9M26, the strong growth from high-complexity revenue lfited the segment contritbution to revenue to 28% (vs 9M24: 24%), while SILO’s revenue per patient day rose 10.2%. The stronger revenue intensity supported 8.2% MIKA’s EBITDA growth of 8.2% and SILO’s 17.8%, translating into net profit growths of 6.7% and 22.1% respectively. In contrast, HEAL’s revenue per inpatient day declined 1%, despite rising revenue contribution from non-BPJS patients. While stronger revenue intensity cannot indefinitely compensate for weak utilisation, the earnings resilience at MIKA and SILO challenges the narrative of a sector in structural earnings decline.
- Slower demand growth puts greater emphasis on asset productivity. In 9M26, HEAL expanded its bed capacity by 8.2% against just a 3.2% growth in inpatient days, while MIKA’s inpatient days fell 6% despite a 1.6% capacity increase. Consequently, HEAL’s bed occupancy rates (BOR) fell by 3.7ppt to 67.9% and MIKA’s BOR dropped 4.2ppt to 52.6%, while SILO’s remained broadly stable at 62.5%. The trade-off between expansion and shareholder returns is becoming increasingly evident - MIKA’s ROIC (excluding landbank) fell to 37.9% from 42.4%, higher depreciation drove HEAL’s 14.8% yoy net profit decline in 9M26, and SILO’s hospital property acquisitions materially increased its financial leverage, with net gearing ratio rising to 55.2% at end-Sep 26 from 4.8% at end-25.
OVERWEIGHT (Maintained)
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.





